Zeltiq Co-Founder Dr. Scott Wolf Joins Life Care Medical Devices Board of Directors
NEW SMYRNA BEACH, FL (PRWEB) March 02, 2017 -- Life Care Medical Devices Limited, (“Life Care,” “LCMD” or the “Company”) a medical device company focused on the development, production and distribution of novel aesthetic medicine devices, today announced that Dr. Scott Wolf has joined the company’s board of directors.
“As a prolific medical device entrepreneur and physician, Scott brings a wealth of experience and background in the aesthetic device market which will help Life Care continue to grow and become one of the premier global aesthetic medicine device companies,” said Richard J. Prati, Chief Executive Officer of Life Care. “We are very enthusiastic to be able to tap into Scott’s vast knowledge and experience in developing aesthetic devices and procedures and believe his addition to our board brings a new level of expertise to the Life Care team.”
Dr. Wolf is an entrepreneur who over the past 20 years has founded numerous successful medical device companies across a broad range of therapeutic areas. Dr. Wolf is a founder of Zeltiq Aesthetics, the maker of CoolSculpting®, the leading non-invasive method of fat reduction for bodysculpting. Zeltiq was recently acquired by Allergan for $2.5 billion. Dr. Wolf’s other startups include Endogastric Solutions and Cardiac Dimensions. He was previously a partner at Prospect Venture Partners and a Vice-President at Frazier Healthcare Ventures, both leading life science venture capital firms. He received his M.D. from George Washington University and his B.A. from the University of Pennsylvania.
About Life Care Medical Devices Limited
Life Care Medical Devices Limited (LCMD), is a medical device company focused on the development, production and distribution of non-invasive and minimally-invasive technologies and products that address the huge consumer demand for aesthetic medicine procedures. The Company’s lead product uses the company’s proprietary electromagnetic radiofrequency induction technology for multiple aesthetic and medical applications. Life Care is also actively pursuing a robust growth strategy to expand its portfolio through the acquisition of synergistic products and technologies in the rapidly growing aesthetic medicine market. For more information, please visit http://www.lcmd.com and connect with the Company on Twitter, Facebook and LinkedIn.
Forward Looking Statements
This press release may contain forward-looking statements regarding our prospective performance. Forward-looking statements are based on certain assumptions and describe future plans, strategies, and expectations of our company. Accordingly, actual results may differ materially from anticipated results. Some of the factors that could cause our actual results to differ from our expectations include, without limitation: the ability to receive FDA and foreign regulatory approvals for our product candidates, including the LapCap2® Laparoscopic Access Device; the unpredictability of the size of the markets for, and market acceptance of, any of our products, including the LapCap2® Laparoscopic Access Device; our ability to produce and sell any approved products and the price we are able to realize for those products; our ability to enter into and maintain collaborations with third parties for the development and commercialization of our products, including the LapCap2® Laparoscopic Access Device; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our ability to retain and hire necessary employees and to staff our operations appropriately; and our dependence on the success of the LapCap2® Laparoscopic Access Device.
Investor Relations
Life Care Medical Devices Limited
Richard J. Prati, CEO
Phone: (386) 410-4239
Email: rprati(at)lcmd(dot)com
Media Contact
Razor Sharp PR
Ray Young
Phone: 512.633.6855
Email: ray(at)razorsharppr(dot)com
# # #
Ray Young, Razor Sharp PR, http://www.razorsharppr.com, +1 (512) 633-6855, [email protected]
Share this article